Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)

FIBRONEER™-ON: ClinicalTrials.gov: NCT06238622, registered 2 February 2024. Protocol version and date: version 3.0, 29 Apr 2024. FIBRONEER™-IPF: ClinicalTrials.gov: NCT05321069, registered 11 March 2022.FIBRONEER™-ILD: ClinicalTrials.gov: NCT05321082, registered 11 March 2022.

Authors

Institutions

Publication Details

Journal
BMC Pulmonary Medicine
Published
2025-12-04
DOI
https://doi.org/10.1186/s12890-025-03973-7
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)

Anna‐Maria Hoffmann‐Vold, Michael Kreuter, Justin M. Oldham, Wim Wuyts et al.
BMC Pulmonary Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)

Anna‐Maria Hoffmann‐Vold, Michael Kreuter, Justin M. Oldham, Wim Wuyts, Luca Richeldi, Shervin Assassi, Carl Coeck, Vincent Cottin, Marlies Wijsenbeek, Arata Azuma, Toby M. Maher, Carmen Valenzuela, Madhu Kanakapura, Gerrit Weimann, Fernando J. Martinez, Alexandra James, Cyril Drzewuski
article en

Abstract

FIBRONEER™-ON: ClinicalTrials.gov: NCT06238622, registered 2 February 2024. Protocol version and date: version 3.0, 29 Apr 2024. FIBRONEER™-IPF: ClinicalTrials.gov: NCT05321069, registered 11 March 2022.FIBRONEER™-ILD: ClinicalTrials.gov: NCT05321082, registered 11 March 2022.

BMC Pulmonary MedicineVol. 26(1)
Université Claude Bernard Lyon 1 (FR), Università Cattolica del Sacro Cuore (IT), Oslo University Hospital (NO), Boehringer Ingelheim (Germany) (DE), Johannes Gutenberg University Mainz (DE), Cornell University (US), Keck Hospital of USC (US), Erasmus MC (NL), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR), University Medical Center of the Johannes Gutenberg University Mainz (DE), Michigan Medicine (US), Boehringer Ingelheim (Belgium) (BE), Hospital Universitario de La Princesa (ES), Hôpital Louis Pradel (FR), Boehringer Ingelheim (France) (FR), Boehringer Ingelheim (China) (CN), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Social Insurance Saitama Chuo Hospital (JP), Imperial College London (GB), Nippon Medical School (JP), KU Leuven (BE)
Openalex Percentile: Top 43%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.